Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Hamad Medical Corporation
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03040765CT.gov Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis | — | Terminated | — | — | — |
NCT02559648CT.gov Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis | — | Completed | — | — | — |
NCT00925600CT.gov Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss | — | Completed | — | — | — |
NCT00980174CT.gov Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteoporosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Denosumab (this asset) | Hamad Medical Corporation | P3 | BB · 66 |
| Risedronic Acid | Susan L. Greenspan | P4 | BBB |
| Zoledronate | California Pacific Medical Center Research Institute | P4 | BBB |
| Vitamin D | Benha University | P4 | BBB |
| Alendronic Acid | University College Dublin | P4 | BBB |
| Calcium | Benha University | P4 | BBB |
| Medroxyprogesterone | Peking Union Medical College Hospital | P4 | BBB |
| Letrozole | Shanghai Jiao Tong University School of Medicine | P3 | BB |
| Raltegravir | St Vincent's Hospital, Sydney | P4 | BB |
+42 more in the Osteoporosis cohort
Other indications for Denosumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Carcinoma In The Bone | — | P4 | BBB · 79 |
| Breast Carcinoma | — | P3 | BB · 70 |
| Castration-Resistant Prostate Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Denosumab in Osteoporosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/denosumab-osteoporosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →